Publikasi Scopus 2024 per tanggal 31 Mei 2024 (409 artikel)

177

Authors

Pollock C.; Moon J.-Y.; Ngoc Ha L.P.; Gojaseni P.; Ching C.H.; Gomez L.; Chan T.M.; Wu M.-J.; Yeo S.C.; Nugroho P.; Bhalla A.K.

Author_Full_Names

Pollock, Carol (7102646018); Moon, Ju-young (7403231326); Ngoc Ha, Le Pham (58866690700); Gojaseni, Pongsathorn (57213457888); Ching, Chen Hua (58867131800); Gomez, Lynn (57216877753); Chan, Tak Mao (57196148620); Wu, Ming-Ju (24482826800); Yeo, See Cheng (57222625225); Nugroho, Pringgodigdo (55987056300); Bhalla, Anil Kumar (56234391400)

Author S Id

7102646018; 7403231326; 58866690700; 57213457888; 58867131800; 57216877753; 57196148620; 24482826800; 57222625225; 55987056300; 56234391400

Title

Framework of Guidelines for Management of CKD in Asia

Year

2024

Source Title

Kidney International Reports

Volume

Issue

Art No

Page Start

752

Page End

790

Page Count

Cited By

Link

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85184170023&doi=10.1016%2fj.ekir.2023.12.010&partnerID=40&md5=d910a1f57586940b850b69b60735230c

Affiliations

Kolling Institute of Medical Research, University of Sydney, St Leonards, NSW, Australia; Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong, Seoul, South Korea; University of Medicine and Pharmacy, Ho Chi Minh City, Viet Nam; Bhumibol Adulyadej Hospital, Bangkok, Thailand; Hospital Sultanah Bahiyah, Kedah, Alor Setar, Malaysia; Asian Hospital and Medical Center, Metro Manila, Muntinlupa City, Philippines; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong; Taichung Veterans General Hospital, Taichung City, Taiwan; Tan Tock Seng Hospital Pte Ltd, Singapore; Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Department of Nephrology-Sir Ganga Ram Hospital Marg, Delhi, New Delhi, India

Authors With Affiliations

Pollock C., Kolling Institute of Medical Research, University of Sydney, St Leonards, NSW, Australia; Moon J.-Y., Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong, Seoul, South Korea; Ngoc Ha L.P., University of Medicine and Pharmacy, Ho Chi Minh City, Viet Nam; Gojaseni P., Bhumibol Adulyadej Hospital, Bangkok, Thailand; Ching C.H., Hospital Sultanah Bahiyah, Kedah, Alor Setar, Malaysia; Gomez L., Asian Hospital and Medical Center, Metro Manila, Muntinlupa City, Philippines; Chan T.M., Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong; Wu M.-J., Taichung Veterans General Hospital, Taichung City, Taiwan; Yeo S.C., Tan Tock Seng Hospital Pte Ltd, Singapore; Nugroho P., Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Bhalla A.K., Department of Nephrology-Sir Ganga Ram Hospital Marg, Delhi, New Delhi, India

Abstract

[No abstract available]

Author Keywords

Asia; chronic kidney disease; diagnosis; management; recommendations; screening

Index Keywords

angiotensin receptor antagonist; anticoagulant agent; antilipemic agent; antithrombocytic agent; calcimimetic agent; dipeptidyl carboxypeptidase inhibitor; finerenone; hemoglobin A1c; hypoxia inducible factor prolyl hydroxylase inhibitor; metformin; parathyroid hormone; sodium glucose cotransporter 2 inhibitor; vitamin D derivative; adverse event; adverse outcome; albumin to creatinine ratio; anemia; anticoagulant therapy; Article; Asia; blood pressure regulation; bone density; bone disease; cardiovascular disease; chronic kidney failure; conceptual framework; disease surveillance; fluid balance; glucose blood level; glycemic control; health care policy; health care quality; human; hyperglycemia; hypertension; insulin dependent diabetes mellitus; lifestyle modification; Mesoamerican nephro

Funding Details

AstraZeneca Singapore Pte Ltd; Fortrea Scientific Pvt. Ltd.; AstraZeneca

Funding Text

The authors would like to thank Ms. Prajakta Nachane (M. Pharm) and Dr. Sushma Jayan (PhD), Fortrea Scientific Pvt. Ltd. (formerly Labcorp Scientific Services and Solutions Pvt. Ltd.) for medical writing support that was funded by AstraZeneca in accordance with GPP 2022 guidelines. The manuscript support was funded by AstraZeneca Singapore Pte Ltd (Asia Area).

Publisher

Elsevier Inc.

Issn

24680249

Isbn

Pubmed Id

Document Type

Article

Sjr Best Quartile

Sjr

1173

Sjr Rank

3200